BioSpecifics Technologies Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 12/2/2020)
Today's Range
50-Day Range
52-Week Range
Average Volume61,105 shs
Market Capitalization$650.25 million
P/E Ratio37.51
Dividend YieldN/A

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter.

BioSpecifics Technologies logo

About BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.11 out of 5 stars

Medical Sector

618th out of 2,220 stocks

Pharmaceutical Preparations Industry

305th out of 869 stocks

Analyst Opinion: 1.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

Is BioSpecifics Technologies a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BioSpecifics Technologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BSTC, but not buy additional shares or sell existing shares.
View analyst ratings for BioSpecifics Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than BioSpecifics Technologies?

Wall Street analysts have given BioSpecifics Technologies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioSpecifics Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to analysts' expectations of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%.
View BioSpecifics Technologies' earnings history

What price target have analysts set for BSTC?

1 Wall Street analysts have issued 12-month price objectives for BioSpecifics Technologies' stock. Their forecasts range from $88.50 to $88.50. On average, they expect BioSpecifics Technologies' share price to reach $88.50 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for BioSpecifics Technologies
or view top-rated stocks among Wall Street analysts.

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the following people:
  • Dr. Ronald Law J.D., Ph.D., Sr. VP of Bus. Devel. (Age 67, Pay $487.38k)
  • Mr. Joseph Truitt, CEO & Director (Age 55)
  • Mr. Patrick C. Hutchison, Chief Financial Officer (Age 61)
  • Mr. Alex Monteith, Sr. VP & Chief Bus. Officer
  • Carl A. Valenstein, Corp. Sec.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $88.53.

How much money does BioSpecifics Technologies make?

BioSpecifics Technologies has a market capitalization of $650.25 million and generates $38.19 million in revenue each year. The biopharmaceutical company earns $24.47 million in net income (profit) each year or $3.33 on an earnings per share basis.

How many employees does BioSpecifics Technologies have?

BioSpecifics Technologies employs 7 workers across the globe.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is

Where are BioSpecifics Technologies' headquarters?

BioSpecifics Technologies is headquartered at 2 Righter Parkway Suite 200, Wilmington DE, 19803.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 2 Righter Parkway Suite 200, Wilmington DE, 19803. The biopharmaceutical company can be reached via phone at 302-842-8450 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.